A New Monoclonal Antibody for Ulcerative Colitis and Crohn's Disease

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 114, Nº. 9, 2014, págs. 25-25
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * Vedolizumab (Entyvio) is a newly approved treatment for adults with moderate-to-severe ulcerative colitis or moderate-to-severe Crohn's disease when standard therapies haven't been successful.

    * The most common adverse effects are nasopharyngitis, headache, joint pain, nausea, and fever. Vedolizumab can also produce hypersensitivity (anaphylactic) and infusion-related reactions, hepatotoxicity, and progressive multifocal leukoencephalopathy.